The chart is not accessible to screen readers. Please switch to the table view to access the data.
Advertisement
Advertisement
Selected pharmaceutical companies by number of Alzheimer's drugs in development as of September 2019
Pharmaceutical companies with Alzheimer's drugs in development 2019
As of September 2019, U.S. pharmaceutical company Eli Lilly had six drugs in development for the treatment of Alzheimer's disease in various stages of clinical trials, followed by Biogen with five drugs in development.
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Statistics on
About the industry
10
- Premium Statistic Prescription spending per capita for 65+ year-olds in U.S. by insurance 2010-2020
- Basic Statistic Phase 2 and 3 trials in Alzheimer’s drug development by region 2025
- Basic Statistic Number of new medicines in R&D pipeline worldwide 2021-2023, by phase
- Basic Statistic Outlook for top narcolepsy products in the global market 2020-2026
- Premium Statistic Orphan vs. non-orphan pipeline sales forecast worldwide 2025-2030
- Basic Statistic Alzheimer’s disease drugs in trial phase III by mechanism of action 2025
- Basic Statistic Alzheimer’s disease therapies in phase II development 2025, by type
- Basic Statistic Alzheimer’s disease drugs in trial phase II by mechanism of action 2025
- Premium Statistic Clinical phase Alzheimer’s disease drugs 2025, by sponsor
- Premium Statistic Time from R&D start to approval of select cancer drugs 2017
About the region
10
- Basic Statistic R&D cost to develop new pharmaceutical compounds 2010-2020
- Basic Statistic Clinical trials initiated worldwide 2018-2024, by trial phase
- Basic Statistic Number of companies conducting endometriosis clinical trials worldwide 2010-2019
- Premium Statistic Percentage return on R&D among large cap biopharma companies 2010-2020
- Basic Statistic Oncology biomarker clinical trial CAGR globally 2000-2018, by cancer type
- Basic Statistic AstraZeneca's number of animals used for research purposes 2006-2025
- Premium Statistic Outsourced research penetration in pharmaceutical industry worldwide 2011-2020
- Premium Statistic Clinical trials initiated worldwide 2018-2024
- Premium Statistic Global pharmaceutical R&D spending vs US and China 2014-2023
- Premium Statistic Market cap of select pharma companies with strong pipeline 2017
Selected statistics
10
- Premium Statistic Clinical trial success rates by therapeutic area 2020
- Premium Statistic R&D expenditure of new therapeutic drugs 2009-2018
- Premium Statistic Number of orphan designations accepted in the U.S. 2003-2025
- Basic Statistic Estimated clinical trial cost per patient by therapeutic class 2015-2017
- Basic Statistic Estimated clinical trial cost per drug by therapeutic class 2015-2017
- Premium Statistic Top 10 companies by global revenue from orphan drugs 2030
- Basic Statistic Number of registered clinical studies by location worldwide 2026
- Basic Statistic Pharmaceutical spending per capita in selected countries 2024
- Basic Statistic Increase in clinical trials' complexity 2001-2015
- Basic Statistic Pharmaceutical sales from patented and non-patented drugs in Canada 2004-2024
Other regions
10
- Premium Statistic U.S. pharma industry R&D expenditure 1980-2024
- Premium Statistic U.S. pharmaceutical industry spending on research and development 1990-2024
- Basic Statistic Biopharmaceutical industry employment total impact U.S. 2010 and 2022
- Premium Statistic Research & development spending on drug development in the U.S. 2024
- Basic Statistic Canadian drug market sales contribution of patented drugs 1990-2024
- Basic Statistic Number of applications for drug reimbursement in Denmark 2013-2022
- Basic Statistic Forecast major categories of U.S. healthcare expenditures 2015-2020
- Basic Statistic Number of declined drug reimbursement applications in Denmark 2013-2022
- Basic Statistic Number of approved drug reimbursement applications in Denmark 2013-2022
- Premium Statistic Top metropolitan areas by largest employment in drugs and pharmaceuticals 2023
Related statistics
10
- Premium Statistic Massachusetts' medical cannabis spending 2018-2024
- Basic Statistic Active immuno-oncological agents in development U.S. 2019, by type
- Basic Statistic Clinical trial participants U.S. vs. rest of world by age group 2015-2019
- Basic Statistic Number of active trials in Alzheimer's Disease pipeline 2022, by product type
- Basic Statistic Orphan and non-orphan drugs in the pipeline worldwide 2021
- Basic Statistic Average number of site per drug trial started worldwide 2015-2020, by phase
- Basic Statistic Key technologies in Alzheimer's Disease clinical trials 2021
- Premium Statistic Number of drug shortages in Canada in selected months 2017-2020
- Premium Statistic Global forecast of outpatient COVID-19 antiviral and Mabs treatments 2020-2026
- Basic Statistic Distribution of reasons for drug shortages in Canada 2017-2020
Further Content: You might find this interesting as well
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
BioSpace. (September 23, 2019). Selected pharmaceutical companies by number of Alzheimer's drugs in development as of September 2019 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 29, 2026, from /statistics/1093282/pharma-companies-developing-alzheimers-drugs-us/
BioSpace. "Selected pharmaceutical companies by number of Alzheimer's drugs in development as of September 2019." Chart. September 23, 2019. ÌÇÐÄÆƽâ°æ. Accessed July 29, 2026. /statistics/1093282/pharma-companies-developing-alzheimers-drugs-us/
BioSpace. (2019). Selected pharmaceutical companies by number of Alzheimer's drugs in development as of September 2019. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 29, 2026. /statistics/1093282/pharma-companies-developing-alzheimers-drugs-us/
BioSpace. "Selected Pharmaceutical Companies by Number of Alzheimer's Drugs in Development as of September 2019." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 23 Sep 2019, /statistics/1093282/pharma-companies-developing-alzheimers-drugs-us/
BioSpace, Selected pharmaceutical companies by number of Alzheimer's drugs in development as of September 2019 ÌÇÐÄÆƽâ°æ, /statistics/1093282/pharma-companies-developing-alzheimers-drugs-us/ (last visited July 29, 2026)
Selected pharmaceutical companies by number of Alzheimer's drugs in development as of September 2019 [Graph], BioSpace, September 23, 2019. [Online]. Available: /statistics/1093282/pharma-companies-developing-alzheimers-drugs-us/
Advertisement